Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eight Talking Points From ESMO

Seattle Genetics scores victory for mid-caps and more

Executive Summary

Proving once again that it is a match for ASCO, here are highlights from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona from 27 September to 1 October.

You may also be interested in...



Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint

A first look at data from Merck & Co’s KEYNOTE-522 trial of Keytruda in early triple-negative breast cancer showed significant pathological response rates and hinted at good things to come in event-free survival, but experts at ESMO want more mature data.

Lynparza Poised To Bring Targeted Therapy To Prostate Cancer

The detailed data from PROfound showed the PARP inhibitor doubled the time to radiographic progression-free survival in men with homologous recombination repair (HRRm) gene mutations.

Bladder Cancer: Positive Signs For Tecentriq, Seattle Genetics Shines

Middling data for Roche’s IO plus chemo combo were presented at ESMO, while Seattle's rival drug antibody conjugate posted an impressive Phase I response rate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel